Conference Coverage
Conference Coverage
Hormone therapy less effective in menopausal women with obesity
It’s unclear whether the treatment itself is less effective or whether the women are not receiving an adequate dosage, because women with obesity...
Conference Coverage
False-positive Pap smear may indicate genitourinary syndrome
Nearly all of the women who received local estrogen treatment had a normal Pap smear following therapy.
Latest News
Spironolactone safe, effective option for women with hidradenitis suppurativa
“Combining different treatment options that target different pathophysiologic factors is usually required to achieve adequate disease control in...
Conference Coverage
CBT effectively treats sexual concerns in menopausal women
Though a small study, the findings confirm previous research results found in women with sexual concerns after gynecologic cancer.
Conference Coverage
Metformin treatment shows benefit in gestational diabetes
“Gestational diabetes is now reaching epidemic proportions. And of course, the vast majority of these women are in low- and middle-income...
Conference Coverage
Hyaluronic acid suppository improves menopause symptoms
HLA may be a promising nonhormonal therapy for this condition, the researchers said.
Conference Coverage
Menopausal hormone therapy less prescribed for Black women
There’s likely a combination of reasons for these disparities, with both provider and patient factors contributing, researchers say.
Conference Coverage
This symptom signals UTI in 83% of cases
“Why has something so clear, so frequently present, never been described? The answer is simple: Physicians and patients do not talk about sex.”
Conference Coverage
New risk factors for cardiovascular disease in women emerging
Gender equity in care for cardiovascular disease will be achieved only when risk factors are evaluated from a gender-dependent perspective and...
Latest News
Can skin bleaching lead to cancer?
Prevalence of skin bleaching in several African countries ranged from 25% in Mali (based on a 1993 survey of 210 women) to a high of 79.25% in...
Conference Coverage
MS drugs during pregnancy show no safety signals
Data on outcomes from cladribine, ocrelizumab, ofatumumab, and ozanimod during pregnancy showed no miscarriages or malformations above the general...